Registry update — unassessed
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Oct 2, 2026 · Discovered: Oct 2, 2026 · Assessed: — · Research update
What it does not prove
- This is a protocol proposal, not a completed study with results; no efficacy or safety data are reported. The study hypothesizes benefit based on prior work in normal kidney function and animal models, but translation to moderate-to-severe CKD remains untested. Sample size, power calculation, and primary outcome effect estimates are not provided, making it impossible to assess whether the proposed design is adequate.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 3 months
- Population
- Patients with stage III and IV chronic kidney disease (CKD), ages 35-80 years
- Primary outcome
- Carotid to femoral artery pulse wave velocity (CFPWV)
- Effect size
- —
- Significance
- Not reported
- Journal
- University of Colorado, Denver
- Published
- Oct 2, 2026
Sources
Primary source
- University of Colorado, Denver ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
A randomized, placebo-controlled, double-blind, single-site phase IIa clinical trial to assess the safety and efficacy of oral nicotinamide riboside (500 mg capsules 2x/day; NIAGEN®; ChromaDex Inc.) for 3 months vs. placebo for decreasing aortic stiffness and SBP in patients (35-80 years) with stage III and IV CKD is being proposed.
Aim 1: To measure CFPWV (primary outcome) before/after nicotinamide riboside vs. placebo treatment; Aim 2: To measure casual and 24h-ambulatory SBP (secondary outcome) before and after treatment; Aim 3: To determine the safety and tolerability of treatment with nicotinamide riboside vs. placebo; Aim 4: To measure systemic NAD+ and NAD+-related metabolite concentrations, as well as circulating markers of oxidative stress, inflammation, and vasoconstriction factors before and after treatment.
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.